Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 28

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 28
---
 Aptorum is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum now focuses all of its efforts on R&D. In the past, Aptorum had provided clinic services. While Aptorum may re -commenceclinic services in the future, as of December 31, 2024 and the date hereof, it only operates in one segment. Aptorum’s goal is to develop a broad range of novel and repurposed therapeutics and diagnostics technology across a wide range of disease/therapeutic areas. Key components of its strategy for achieving this goal include: (for details of Aptorum’s strategy, See “Information about Aptorum — Aptorum’s Strategy”) •Developing therapeutic and diagnostic innovations across a wide range of disease/therapeutic areas; •Selectively expanding Aptorum’s portfolio with potential products that may be able to attain orphan drug designation and/or satisfy current unmet medical needs; •Collaborating with leading academic institutions and CROs; •Expanding Aptorum’s in -housepharmaceutical development center; •Leveraging Aptorum’s management’s expertise, experience and commercial networks; •Obtaining and leveraging government grants to fund project development. Aptorum’s Lead Projects are ALS -4and SACT -1. In March 2023, Aptorum announced that it completed the Pre -INDdiscussions with the US FDA on ALS -4. With the positive feedback on the overall development strategy from the US FDA, it is proceeding towards the IND submission of ALS -4. In March 2023, Aptorum also announced the completion of the End of Phase 1 (EOP1) meeting of SACT -1with the US FDA. The FDA generally agreed with the chemistry -manufacturing -control(CMC) strategy and Aptorum’s proposed clinical development plan for SACT -1Phase 1/2 trials. Currently, ALS -4and SACT -1are Phase 2 clinical trials ready. During the second quarter of 2023, Aptorum decided to streamline its operations by terminating clinic services and suspending non -leadR&D projects. This was done to optimize the allocation of Aptorum’s resources and focusing efforts on advancing Aptorum’s lead projects, which hold the most promise for commercial success and beneficial impact. This decision aligns with its commitment to enhance shareholder value and effectively drive its core